Prediction of Extensive Myocardial Fibrosis in Nonhigh Risk Patients With Hypertrophic Cardiomyopathy

Autor: Rudolf A. de Boer, Hendrik-Jan Dieker, D.H. Frank Gommans, Marc A. Brouwer, G. Etienne Cramer, Menko-Jan de Boer, Michael A. Fouraux, Marcel J.M. Kofflard, Jeannette Bakker, Freek W.A. Verheugt, Carlo Marcelis, Janneke Timmermans, Michelle Michels
Přispěvatelé: Cardiology, Cardiovascular Centre (CVC)
Rok vydání: 2018
Předmět:
Male
medicine.medical_treatment
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
Cardiomyopathy
030204 cardiovascular system & hematology
GUIDELINES
Ventricular tachycardia
SUDDEN-DEATH RISK
Ventricular Function
Left
0302 clinical medicine
Risk Factors
TROPONIN-T
030212 general & internal medicine
medicine.diagnostic_test
Troponin T
Hypertrophic cardiomyopathy
Middle Aged
Endomyocardial Fibrosis
Prognosis
Implantable cardioverter-defibrillator
EUROPEAN-SOCIETY
PROGNOSTIC VALUE
CARDIOVASCULAR MAGNETIC-RESONANCE
Predictive value of tests
embryonic structures
Cardiology
Female
Cardiology and Cardiovascular Medicine
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Adult
medicine.medical_specialty
Heart Ventricles
BIOMARKERS
Magnetic Resonance Imaging
Cine
03 medical and health sciences
ENHANCEMENT
Predictive Value of Tests
Internal medicine
medicine
Humans
cardiovascular diseases
Retrospective Studies
GALECTIN-3
business.industry
Myocardium
Magnetic resonance imaging
Retrospective cohort study
Cardiomyopathy
Hypertrophic
medicine.disease
ROC Curve
business
human activities
Follow-Up Studies
TASK-FORCE
Zdroj: American Journal of Cardiology, 122, 3, pp. 483-489
American Journal of Cardiology, 122(3), 483-489. Elsevier Inc.
American Journal of Cardiology, 122, 483-489
American Journal of Cardiology, 122(3), 483-489. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2018.04.020
Popis: Contains fulltext : 196255.pdf (Publisher’s version ) (Open Access) In nonhigh risk patients with hypertrophic cardiomyopathy (HC), the presence of extensive late gadolinium enhancement (LGEext) at cardiovascular magnetic resonance (CMR) imaging has been proposed as a risk modifier in the decision process for implantable cardioverter defibrillator implantation. With a pretest risk of about 10%, a strategy that alters the likelihood of LGEext could markedly affect efficacious CMR imaging. Our aim was to study the potential of clinical variables and biomarkers to predict LGEext. In 98 HC patients without any clear indication for implantable cardioverter defibrillator implantation, we determined the discriminative values of a set of clinical variables and a panel of biomarkers (hs-cTnT, NTproBNP, GDF-15, and Gal-3, CICP) for LGEext, that is, LGE >/=15% of the left ventricular mass. LGEext was present in 10% (10/98) of patients. The clinical prediction model contained a history of nonsustained ventricular tachycardia, maximal wall thickness and reduced systolic function (c-statistic: 0.868, p
Databáze: OpenAIRE
Externí odkaz: